Quality Management Maturity for Finished Dosage Forms Pilot Program for Domestic Drug Product Manufacturers; Program Announcement, 65824-65825 [2020-22976]

Download as PDF 65824 Federal Register / Vol. 85, No. 201 / Friday, October 16, 2020 / Notices Dated: October 13, 2020. Lauren K. Roth, Acting Principal Associate Commissioner for Policy. [FR Doc. 2020–22968 Filed 10–15–20; 8:45 am] BILLING CODE 4164–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2020–N–2031] Quality Management Maturity for Finished Dosage Forms Pilot Program for Domestic Drug Product Manufacturers; Program Announcement AGENCY: Food and Drug Administration, HHS. ACTION: Notice. The Food and Drug Administration (FDA or Agency), Center for Drug Evaluation and Research (CDER) is announcing its Quality Management Maturity for Finished Dosage Forms Pilot Program (QMM FDF Pilot Program) for domestic drug product manufacturers of prescription and over-the-counter (OTC) drug products. The purpose of the QMM FDF Pilot Program is to gain insight from third-party assessments of a manufacturer’s quality management system to inform future development of an FDA rating system to characterize quality management maturity (QMM). Such a rating system would allow a cross-sectional comparison of manufacturers. Manufacturers that choose to disclose their facility ratings could benefit from a competitive advantage, as knowledge of QMM ratings would enable health systems and other purchasers and payers of medications to differentiate among drug manufacturers. This notice invites manufacturers that are interested in participating in the QMM FDF Pilot Program to submit a request to participate. SUMMARY: FDA will accept requests to participate in the QMM FDF Pilot Program through November 30, 2020, and the QMM FDF Pilot Program will run through December 31, 2021. See the ‘‘Participation’’ section for selection criteria and instructions on how to submit a request to participate. FOR FURTHER INFORMATION CONTACT: For general questions about the QMM FDF Pilot Program: Jennifer Maguire, Center for Drug Evaluation and Research (CDER), 10903 New Hampshire Ave., Silver Spring, MD 20993, Bldg. 51, Rm. jbell on DSKJLSW7X2PROD with NOTICES DATES: VerDate Sep<11>2014 18:59 Oct 15, 2020 Jkt 253001 4134, 240–402–4817, Jennifer.Maguire@ fda.hhs.gov. To submit a request to participate in the QMM FDF Pilot Program: Seongjin (Cindy) Pak, CDER, Bldg. 51, Rm. 4220, 301–796–1673, Seongjin.Pak@ fda.hhs.gov. SUPPLEMENTARY INFORMATION: I. Background In 2002, FDA launched an initiative, ‘‘Pharmaceutical CGMPs for the 21st Century—A Risk-Based Approach,’’ to enhance and modernize the regulation of pharmaceutical manufacturing and product quality.1 One objective, among others, was to facilitate the implementation of a modern, risk-based pharmaceutical quality assessment system. The desired state has been described as a maximally efficient, agile, flexible pharmaceutical manufacturing sector that reliably produces highquality drug products without extensive regulatory oversight. There has been significant progress toward this vision as evidenced by FDA programs and initiatives in such areas as pharmaceutical development and quality by design, quality risk management and pharmaceutical quality systems, process validation, and emerging technologies. These programs and initiatives promote use of the best pharmaceutical science and engineering principles throughout the product life cycle. Another example is the FDA Quality Metrics Program, described in the November 2016 revised draft guidance for industry ‘‘Submission of Quality Metrics Data’’ (81 FR 85226). When final, this guidance will represent FDA’s current thinking on this issue. In June 2018, FDA initiated two voluntary programs that sought additional industry input on quality metrics. FDA solicited industry participation for a Site Visit Program (83 FR 30751) for manufacturing establishments to present the advantages and challenges associated with implementing and managing a quality metrics program, and for a Quality Metrics Feedback Program (83 FR 30748) to engage stakeholders in identifying mutually useful and objective quality metrics. The Agency continues to develop the FDA Quality Metrics Program but recognizes that quality metrics are only one element within a manufacturer’s larger effort to increase the maturity of their quality management system. Manufacturers that demonstrate QMM 1 See FDA’s final report: ‘‘Pharmaceuticals CGMPs for the 21st Century—A Risk-Based Approach’’ (September 2004) at https:// www.fda.gov/media/77391/download. PO 00000 Frm 00037 Fmt 4703 Sfmt 4703 operate under an enhanced quality management system that exceeds the minimum standards specified in current good manufacturing practice regulations and focuses on continual improvement. Characteristics of a mature quality management system include, for example, the ability to consistently and reliably deliver quality product over time, operational stability, and a strong quality culture. Additionally, for manufacturers with a mature quality management system, FDA can exercise a more flexible regulatory approach, leading toward the goal of producing high-quality drug products without extensive regulatory oversight. A transparent method of evaluating and communicating QMM is needed to fully realize the 21st century pharmaceutical quality vision. Toward that end, FDA is announcing the start of the QMM FDF Pilot Program. Through this pilot program, a third-party contractor identified by FDA will conduct an assessment of a manufacturer’s quality management system, accompanied by FDA staff. The Agency will gain insight from the results of the QMM assessments to inform the development of a rating system to measure and rate QMM. Assessments under the QMM FDF Pilot Program will cover multiple topics. Examples include but are not limited to: 1. Supply chain management; 2. manufacturing strategy and operations; 3. safety, environmental, and regulatory compliance; 4. inventory management; 5. performance management and continual improvement; 6. risk management; 7. management review and responsibility; 8. planning; 9. workforce management; 10. quality culture; and 11. customer experience. In the same timeframe as the QMM FDF Pilot Program, FDA will conduct a QMM pilot program for foreign manufacturers of active pharmaceutical ingredients (APIs), including facilities manufacturing drug substance intermediates used to produce APIs. These pilot programs are funded separately and are intended to provide FDA with representative information about QMM from different types of drug manufacturers (API and FDF). Elsewhere in this issue of the Federal Register, FDA is publishing ‘‘Quality Management Maturity for Active Pharmaceutical Ingredients Pilot Program for Foreign Facilities; Program Announcement.’’ E:\FR\FM\16OCN1.SGM 16OCN1 Federal Register / Vol. 85, No. 201 / Friday, October 16, 2020 / Notices II. Participation Drug product manufacturers located in the United States that are interested in participating in the QMM FDF Pilot Program should submit a written request directly to Seongjin (Cindy) Pak (see FOR FURTHER INFORMATION CONTACT). Participation in the QMM FDF Pilot Program is voluntary. Participants in the Quality Metrics Feedback Program are encouraged to participate in the QMM FDF Pilot Program. FDA will select up to nine participants for the QMM FDF Pilot Program. Participation in the QMM FDF Pilot Program is limited to domestic manufacturing facilities since FDA’s funding source for this program is specific to activities related to domestic manufacturing. A. Selection Criteria jbell on DSKJLSW7X2PROD with NOTICES To be considered for the QMM FDF Pilot Program, participants must meet the following selection criteria: 1. Participant is a U.S.-based manufacturing facility of prescription and/or OTC drug products. 2. All FDA inspection(s) of the manufacturing facility conducted within the 5 years prior to October 1, 2020, received a final classification of ‘‘No Action Indicated’’ or ‘‘Voluntary Action Indicated.’’ 3. Participant agrees to: a. Permit a third-party contractor to conduct a QMM assessment, whether the assessment is conducted on-site or remotely. FDA will identify an external contractor having the expertise to assess QMM, and FDA staff will join the contractor for the assessment. b. Collect and submit metrics data to FDA and the contractor by an agreed upon date, prior to the assessment. As part of the scoping discussions for the assessment, FDA will provide the manufacturer with templates and additional details about the data collection. c. Be available for consultations with the contractor and FDA prior to and after the assessment, including discussions regarding the participant’s established QMM-related activities and the contractor’s post-assessment recommendations regarding these activities. During this QMM FDF Pilot Program, the contractor and FDA staff will be available to answer questions and address concerns that arise. B. Information To Include in the Request When submitting a request to participate in the QMM FDF Pilot Program, include the information below to aid in FDA’s selection and planning. VerDate Sep<11>2014 18:59 Oct 15, 2020 Jkt 253001 FDA will not consider requests submitted without the following minimal information: 1. A contact person (name and email); 2. manufacturing facility location; 3. facility FDA Establishment Identifier and Data Universal Numbering System numbers; 4. a brief description of the manufacturing operations conducted at the facility; 5. preferred dates for the assessment; 6. written confirmation that the facility meets the selection criteria in section II.A, including agreement to items 3a–c; 7. written confirmation that the facility can handle a visit of up to 10 FDA staff and contractors; and 8. a brief description of prior experiences undergoing an assessment related to the maturity of the facility’s quality culture, including the name of the organization that conducted the assessment and date of the assessment. Dated: October 13, 2020. Lauren K. Roth, Acting Principal Associate Commissioner for Policy. [FR Doc. 2020–22976 Filed 10–15–20; 8:45 am] BILLING CODE 4164–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2018–N–0073] Agency Information Collection Activities; Proposed Collection; Comment Request; Irradiation in the Production, Processing, and Handling of Food AGENCY: Food and Drug Administration, HHS. ACTION: Notice. The Food and Drug Administration (FDA, we, or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection provisions of our requirements for food irradiation processors. SUMMARY: PO 00000 Frm 00038 Fmt 4703 Sfmt 4703 65825 Submit either electronic or written comments on the collection of information by December 15, 2020. ADDRESSES: You may submit comments as follows. Please note that late, untimely filed comments will not be considered. Electronic comments must be submitted on or before December 15, 2020. The https://www.regulations.gov electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of December 15, 2020. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are postmarked or the delivery service acceptance receipt is on or before that date. DATES: Electronic Submissions Submit electronic comments in the following way: • Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https:// www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov. • If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ‘‘Written/Paper Submissions’’ and ‘‘Instructions’’). Written/Paper Submissions Submit written/paper submissions as follows: • Mail/Hand delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. • For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in ‘‘Instructions.’’ Instructions: All submissions received must include the Docket No. FDA– 2018–N–0073 for ‘‘Agency Information E:\FR\FM\16OCN1.SGM 16OCN1

Agencies

[Federal Register Volume 85, Number 201 (Friday, October 16, 2020)]
[Notices]
[Pages 65824-65825]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-22976]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2020-N-2031]


Quality Management Maturity for Finished Dosage Forms Pilot 
Program for Domestic Drug Product Manufacturers; Program Announcement

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency), Center for 
Drug Evaluation and Research (CDER) is announcing its Quality 
Management Maturity for Finished Dosage Forms Pilot Program (QMM FDF 
Pilot Program) for domestic drug product manufacturers of prescription 
and over-the-counter (OTC) drug products. The purpose of the QMM FDF 
Pilot Program is to gain insight from third-party assessments of a 
manufacturer's quality management system to inform future development 
of an FDA rating system to characterize quality management maturity 
(QMM). Such a rating system would allow a cross-sectional comparison of 
manufacturers. Manufacturers that choose to disclose their facility 
ratings could benefit from a competitive advantage, as knowledge of QMM 
ratings would enable health systems and other purchasers and payers of 
medications to differentiate among drug manufacturers. This notice 
invites manufacturers that are interested in participating in the QMM 
FDF Pilot Program to submit a request to participate.

DATES: FDA will accept requests to participate in the QMM FDF Pilot 
Program through November 30, 2020, and the QMM FDF Pilot Program will 
run through December 31, 2021. See the ``Participation'' section for 
selection criteria and instructions on how to submit a request to 
participate.

FOR FURTHER INFORMATION CONTACT: For general questions about the QMM 
FDF Pilot Program: Jennifer Maguire, Center for Drug Evaluation and 
Research (CDER), 10903 New Hampshire Ave., Silver Spring, MD 20993, 
Bldg. 51, Rm. 4134, 240-402-4817, [email protected].
    To submit a request to participate in the QMM FDF Pilot Program: 
Seongjin (Cindy) Pak, CDER, Bldg. 51, Rm. 4220, 301-796-1673, 
[email protected].

SUPPLEMENTARY INFORMATION:

I. Background

    In 2002, FDA launched an initiative, ``Pharmaceutical CGMPs for the 
21st Century--A Risk-Based Approach,'' to enhance and modernize the 
regulation of pharmaceutical manufacturing and product quality.\1\ One 
objective, among others, was to facilitate the implementation of a 
modern, risk-based pharmaceutical quality assessment system. The 
desired state has been described as a maximally efficient, agile, 
flexible pharmaceutical manufacturing sector that reliably produces 
high-quality drug products without extensive regulatory oversight.
---------------------------------------------------------------------------

    \1\ See FDA's final report: ``Pharmaceuticals CGMPs for the 21st 
Century--A Risk-Based Approach'' (September 2004) at https://www.fda.gov/media/77391/download.
---------------------------------------------------------------------------

    There has been significant progress toward this vision as evidenced 
by FDA programs and initiatives in such areas as pharmaceutical 
development and quality by design, quality risk management and 
pharmaceutical quality systems, process validation, and emerging 
technologies. These programs and initiatives promote use of the best 
pharmaceutical science and engineering principles throughout the 
product life cycle.
    Another example is the FDA Quality Metrics Program, described in 
the November 2016 revised draft guidance for industry ``Submission of 
Quality Metrics Data'' (81 FR 85226). When final, this guidance will 
represent FDA's current thinking on this issue. In June 2018, FDA 
initiated two voluntary programs that sought additional industry input 
on quality metrics. FDA solicited industry participation for a Site 
Visit Program (83 FR 30751) for manufacturing establishments to present 
the advantages and challenges associated with implementing and managing 
a quality metrics program, and for a Quality Metrics Feedback Program 
(83 FR 30748) to engage stakeholders in identifying mutually useful and 
objective quality metrics.
    The Agency continues to develop the FDA Quality Metrics Program but 
recognizes that quality metrics are only one element within a 
manufacturer's larger effort to increase the maturity of their quality 
management system. Manufacturers that demonstrate QMM operate under an 
enhanced quality management system that exceeds the minimum standards 
specified in current good manufacturing practice regulations and 
focuses on continual improvement. Characteristics of a mature quality 
management system include, for example, the ability to consistently and 
reliably deliver quality product over time, operational stability, and 
a strong quality culture. Additionally, for manufacturers with a mature 
quality management system, FDA can exercise a more flexible regulatory 
approach, leading toward the goal of producing high-quality drug 
products without extensive regulatory oversight.
    A transparent method of evaluating and communicating QMM is needed 
to fully realize the 21st century pharmaceutical quality vision. Toward 
that end, FDA is announcing the start of the QMM FDF Pilot Program. 
Through this pilot program, a third-party contractor identified by FDA 
will conduct an assessment of a manufacturer's quality management 
system, accompanied by FDA staff. The Agency will gain insight from the 
results of the QMM assessments to inform the development of a rating 
system to measure and rate QMM. Assessments under the QMM FDF Pilot 
Program will cover multiple topics. Examples include but are not 
limited to:
    1. Supply chain management;
    2. manufacturing strategy and operations;
    3. safety, environmental, and regulatory compliance;
    4. inventory management;
    5. performance management and continual improvement;
    6. risk management;
    7. management review and responsibility;
    8. planning;
    9. workforce management;
    10. quality culture; and
    11. customer experience.
    In the same timeframe as the QMM FDF Pilot Program, FDA will 
conduct a QMM pilot program for foreign manufacturers of active 
pharmaceutical ingredients (APIs), including facilities manufacturing 
drug substance intermediates used to produce APIs. These pilot programs 
are funded separately and are intended to provide FDA with 
representative information about QMM from different types of drug 
manufacturers (API and FDF). Elsewhere in this issue of the Federal 
Register, FDA is publishing ``Quality Management Maturity for Active 
Pharmaceutical Ingredients Pilot Program for Foreign Facilities; 
Program Announcement.''

[[Page 65825]]

II. Participation

    Drug product manufacturers located in the United States that are 
interested in participating in the QMM FDF Pilot Program should submit 
a written request directly to Seongjin (Cindy) Pak (see FOR FURTHER 
INFORMATION CONTACT). Participation in the QMM FDF Pilot Program is 
voluntary. Participants in the Quality Metrics Feedback Program are 
encouraged to participate in the QMM FDF Pilot Program. FDA will select 
up to nine participants for the QMM FDF Pilot Program. Participation in 
the QMM FDF Pilot Program is limited to domestic manufacturing 
facilities since FDA's funding source for this program is specific to 
activities related to domestic manufacturing.

A. Selection Criteria

    To be considered for the QMM FDF Pilot Program, participants must 
meet the following selection criteria:
    1. Participant is a U.S.-based manufacturing facility of 
prescription and/or OTC drug products.
    2. All FDA inspection(s) of the manufacturing facility conducted 
within the 5 years prior to October 1, 2020, received a final 
classification of ``No Action Indicated'' or ``Voluntary Action 
Indicated.''
    3. Participant agrees to:
    a. Permit a third-party contractor to conduct a QMM assessment, 
whether the assessment is conducted on-site or remotely. FDA will 
identify an external contractor having the expertise to assess QMM, and 
FDA staff will join the contractor for the assessment.
    b. Collect and submit metrics data to FDA and the contractor by an 
agreed upon date, prior to the assessment. As part of the scoping 
discussions for the assessment, FDA will provide the manufacturer with 
templates and additional details about the data collection.
    c. Be available for consultations with the contractor and FDA prior 
to and after the assessment, including discussions regarding the 
participant's established QMM-related activities and the contractor's 
post-assessment recommendations regarding these activities.
    During this QMM FDF Pilot Program, the contractor and FDA staff 
will be available to answer questions and address concerns that arise.

B. Information To Include in the Request

    When submitting a request to participate in the QMM FDF Pilot 
Program, include the information below to aid in FDA's selection and 
planning. FDA will not consider requests submitted without the 
following minimal information:
    1. A contact person (name and email);
    2. manufacturing facility location;
    3. facility FDA Establishment Identifier and Data Universal 
Numbering System numbers;
    4. a brief description of the manufacturing operations conducted at 
the facility;
    5. preferred dates for the assessment;
    6. written confirmation that the facility meets the selection 
criteria in section II.A, including agreement to items 3a-c;
    7. written confirmation that the facility can handle a visit of up 
to 10 FDA staff and contractors; and
    8. a brief description of prior experiences undergoing an 
assessment related to the maturity of the facility's quality culture, 
including the name of the organization that conducted the assessment 
and date of the assessment.

    Dated: October 13, 2020.
Lauren K. Roth,
Acting Principal Associate Commissioner for Policy.
[FR Doc. 2020-22976 Filed 10-15-20; 8:45 am]
BILLING CODE 4164-01-P